Denhoy Raj
Known title: Chief Financial OfficerCIK: 0001876083
Denhoy Raj's purchase track record
Denhoy Raj has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/17/2023 | ESTA | $50K | +81.8% | +157.1% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ESTA | ▲ Buy | Grant | 11,200 | $0 | 3/13/2025 | View on chart |
| ESTA | ▼ Sell | Tax Withholding | 985 | $41K | 3/6/2025 | View on chart |
| ESTA | ▼ Sell | Tax Withholding | 314 | $17K | 4/10/2024 | View on chart |
| ESTA | ▲ Buy | Grant | 5,644 | $0 | 3/6/2024 | View on chart |
| ESTA | ▼ Sell | Tax Withholding | 309 | $15K | 3/6/2024 | View on chart |
| ESTA | ▲ Buy | Open Market | 2,250 | $50K | 11/17/2023 | View on chart |
| ESTA | ▼ Sell | Tax Withholding | 332 | $23K | 4/10/2023 | View on chart |
| ESTA | ▲ Buy | Grant | 2,986 | $0 | 3/6/2023 | View on chart |
| ESTA | ▲ Buy | Grant | 3,208 | $0 | 4/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ESTA Receives FDA Approval for New Motiva Implant Sizes
Establishment Labs Holdings received FDA clearance for additional sizes of its Motiva implants, expanding its product lineup. The company also reported its Q2 2026 financial results. This regulatory approval is a key development for the medical device maker, potentially broadening its market reach.
ESTA Receives FDA Approval for New Motiva Implant Sizes. Establishment Labs Holdings received FDA clearance for additional sizes of its Motiva implants, expanding its product lineup. The company also reported its Q2 2026 financial results. This regulatory approval is a key development for the medical device maker, potentially broadening its market reach.